Sung Ji Nam
Stock Analyst at Scotiabank
(2.16)
# 2,887
Out of 4,996 analysts
83
Total ratings
43.48%
Success rate
-3.66%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $60.03 | -0.05% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $51.84 | +44.68% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $184.84 | +48.78% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $464.24 | +27.09% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $91.69 | +36.33% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $22.71 | +76.13% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $7.75 | +416.13% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $7.70 | -22.08% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.66 | +140.96% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.21 | +65.29% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $53.57 | +36.27% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $13.22 | -9.23% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $291.71 | +54.26% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $26.91 | +130.40% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $33.44 | +31.58% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $14.94 | +134.27% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $6.07 | -1.15% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.59 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $60.03
Upside: -0.05%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $51.84
Upside: +44.68%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $184.84
Upside: +48.78%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $464.24
Upside: +27.09%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $91.69
Upside: +36.33%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $22.71
Upside: +76.13%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $7.75
Upside: +416.13%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $7.70
Upside: -22.08%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.66
Upside: +140.96%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.21
Upside: +65.29%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $53.57
Upside: +36.27%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $13.22
Upside: -9.23%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $291.71
Upside: +54.26%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $26.91
Upside: +130.40%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $33.44
Upside: +31.58%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $14.94
Upside: +134.27%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $6.07
Upside: -1.15%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $22.59
Upside: -